Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 9/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | SMURF1 | Q9HCE7 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26907939 | 0.88 | MAPT (0.35) | SMN1; SMN2 | |
| SCHEMBL26907881 | 0.86 | MAPT (0.37) | SMN1; SMN2P2RX7 | |
| SCHEMBL26908007 | 0.85 | SMN1; SMN2 (0.40) | SMN1; SMN2P2RX7BRD4PIM1 | |
| SCHEMBL26907842 | 0.85 | S1PR3 (0.35) | BRD4 | |
| SCHEMBL27115424 | 0.84 | KIF11 (0.38) | SMN1; SMN2CHRM5P2RX7BRD4SMURF1 | |
| SCHEMBL26907908 | 0.82 | SMO (0.33) | PIM1 | |
| SCHEMBL26907846 | 0.82 | KCNMA1 (0.37) | SMN1; SMN2 | |
| SCHEMBL26907967 | 0.81 | KCNMA1 (0.41) | SMN1; SMN2 | |
| SCHEMBL26907921 | 0.78 | CHRM4 (0.36) | — | |
| SCHEMBL26907931 | 0.78 | CHRM4 (0.37) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116882-A1 | NOVEL BENZOTRIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE, AND USE THEREOF | TXINNO BIOSCIENCE INC. (KR) | 2024-04-11 | — | — | US | claimed |
| EP-4286374-A1 | NOVEL BENZOTRIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE, AND USE THEREOF | Txinno Bioscience Inc. (KR) | 2023-12-06 | — | — | EP | claimed |
| US-20240116882-A1 | NOVEL BENZOTRIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE, AND USE THEREOF | TXINNO BIOSCIENCE INC. (KR) | 2024-04-11 | — | — | US | disclosed |
| EP-4286374-A1 | NOVEL BENZOTRIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE, AND USE THEREOF | Txinno Bioscience Inc. (KR) | 2023-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116882-A1 | NOVEL BENZOTRIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE, AND USE THEREOF | ENPP1, ENPP3, TPP1 | SMN1; SMN2 2522/4885CHRM5 4443/4885P2RX7 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.